Manas Mishra
Editor-in-Charge, Health and Pharmaceuticals at Reuters
@Reuters. Follow for healthcare/business related news and my obscure interests on your feed. Opinions are mine, and not those of my employer.
Articles
-
1 week ago |
today.westlaw.com | Manas Mishra |Dan Levine |Michael Erman
(Reuters) -The U.S. Food and Drug Administration has named Vinay Prasad, an oncologist who has previously criticized FDA leadership and COVID-19 mandates, as the director of its Center for Biologics Evaluation and Research, the agency said on...
-
1 week ago |
today.westlaw.com | Manas Mishra |Shinjini Ganguli |Sneha K
(Reuters) -Cigna on Friday raised its full-year earnings forecast and beat estimates for quarterly profit, helped by strong performance in its pharmacy benefit management business and lower-than-expected medical costs in its insurance arm. It is the...
-
1 week ago |
bilyonaryo.com | Manas Mishra |Sneha K
SOURCE: ReutersCVS beats profit estimates, aided by strength across businessesMedical loss ratio improves, falling to 87.3% from 90.4%To drop Zepbound from preferred medicines listBy Manas Mishra, Sneha S KMay 1 (Reuters) – CVS Health CVS.N raised its full-year profit forecast on Thursday and said it plans to exit the market for Obamacare health insurance plans in 2026, as it seeks to turn around its fortunes after a series of challenges last year.
-
1 week ago |
kfgo.com | Manas Mishra
By Manas Mishra(Reuters) – CVS Health raised its full-year profit forecast on Thursday following strong performance across its businesses, signaling an early recovery after a series of troubles hit the healthcare conglomerate last year. Shares of the company jumped 8.4% to $72.30 in premarket trading.
-
1 week ago |
finance.yahoo.com | Manas Mishra
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Manas Mishra Thu, May 1, 2025, 5:35 AM 2 min read In This Article: By Manas Mishra (Reuters) - CVS Health raised its full-year profit forecast on Thursday following strong performance across its businesses, signaling an early recovery after a series of troubles hit the healthcare conglomerate last year. Shares of the company jumped 8.4% to $72.30 in premarket trading.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 800
- Tweets
- 377
- DMs Open
- No
RT @Reuters_Health: Staff reviewers at the U.S. Food and Drug Administration said on Wednesday a confirmatory trial did not show the effect…
RT @NancyLapid: Mourning the tragic loss of our brilliant young @Reuters colleague @NatalieGrover.
Novavax struck a licensing deal worth at least $1.2 billion with Sanofi for its COVID-19 vaccine in exchange for a stake that valued it at double its current market capitalization By @BhanviSatija @PatrickWingrove @shubhamkalia93 $NVAX $SNY https://t.co/AcaZPXsLcm